Pennytobuck Stock Report On Enmd, And Prot; Stock Update On Celg And Abii

PROTEONOMIX, INC

PROTEONOMIX, INC. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on their successful international approach to commercializing its proprietary and patent pending stem cell technologies. PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is PROT's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcmarkets.com/ and http://www.sec.gov/.

Celgene Corporation (NASDAQ:CELG) announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regard to Celgenes pending acquisition of Abraxis Bioscience, Inc. (NASDAQ:ABII). CELG, headquartered in Summit, New Jersey is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit CELG's website at www.celgene.com.

ABII is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. ABII's portfolio includes chemotherapeutic compound (ABRAXANE), which is based on ABII's proprietary tumor targeting technology known as the nab platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 39 countries. ABII continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about ABII and its products, please visit http://www.abraxisbio.com.

EntreMed, Inc. (Nasdaq:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010. ENMD reported a net loss for the second quarter of 2010 of ($4.9 million), or ($0.62) per share. This compares with a net loss of ($3.1 million), or ($0.46) per share, for the same period last year. For the first six months of 2010 the reported net loss was ($7.1 million), or ($0.95) per share as compared to ($6.6 million), or ($0.98) per share for 2009.

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on ENMD's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

by: Bill Pennyman

POST COMMENT

Marijuana Law, Fines And Punishment What is the Best Anti Wrinkle Cream and Why You Are Probably Not Using it Yet Stock Update Gg, Ngd, And Orfg - Pennytobuck.com Stock Update On Jmba, Jtx, Csco, Taxs - Pennytobuck.com What Is Scareware and Why Is It a Threat Pennytobuck Stock Report On Pwrm, Genz, Mnkd For August 16th, 2010. Enjoying Bingo Today: Centuries Past And It Is Still Exhilarating Power Inverter Do's And Don'ts What Is A Short Sale And How Does The Process Work? Why go to Boot Camp and not just work out at a gym? Stock Update On Prot, Cur And Teva From Pennytobuck.com The Learners Most Excellent Fundamentals When Knowing Along With Participating Innumerable Enjoyable How Stock Study Evaluation Is Processed